PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
20.86%
Growth of 20.86% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
1550.93%
Cost growth of 1550.93% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify cost control.
-21.47%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
25.04%
Margin change of 25.04% versus flat Drug Manufacturers - Specialty & Generic margins. Walter Schloss would verify quality.
96.49%
R&D change of 96.49% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
145.83%
G&A change of 145.83% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
38.40%
Marketing expense change of 38.40% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
7.42%
Other expenses change of 7.42% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
92.30%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.11%. Jim Chanos would check for waste.
46.90%
Total costs change of 46.90% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
146.44%
Interest expense change of 146.44% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
40.15%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.40%. Jim Chanos would check for overinvestment.
-12.72%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is -1.40%. Seth Klarman would investigate causes.
-262.81%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-27.53%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-40.04%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
529.48%
Other expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 31.87%. Jim Chanos would check for issues.
871.04%
Income change of 871.04% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
737.95%
Margin change of 737.95% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
415.60%
Tax expense change of 415.60% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify strategy.
686.38%
Income change of 686.38% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
585.17%
Margin change of 585.17% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
671.43%
EPS change of 671.43% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
669.28%
Diluted EPS change of 669.28% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.